Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Open Access
- 1 January 2021
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (1), 24-28
- https://doi.org/10.1159/000511071
Abstract
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) reported to show a higher efficacy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) than other TKIs. However, few studies describe ponatinib for pediatric Ph+ALL; therefore, the efficacy, safety, and optimal dosage have not been determined. Here, we report a 3-year-old girl with Ph+ALL treated by a ponatinib-containing regimen with therapeutic drug monitoring in the plasma and cerebrospinal fluid (CSF). In our case, a ponatinib-containing regimen was able to keep minimal residual disease negative, and the pharmacokinetics (PKs) of plasma ponatinib resembled that previously reported in adults. Penetration to the CSF was extremely limited. Thus, ponatinib was feasible and effective for a child with Ph+ALL, although the plasma concentration of ponatinib varied significantly throughout the treatment. The appropriate dosage should be confirmed in a prospective trial, including a detailed PK study.This publication has 9 references indexed in Scilit:
- Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02Blood Cancer Journal, 2020
- Successful treatment with ponatinib for central nervous system relapse of Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemiaInternal Medicine Journal, 2019
- Efficacy and safety of low dose ponatinib in a case of Ph‐positive acute lymphoblastic leukaemiaBritish Journal of Haematology, 2019
- Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622Journal of Clinical Oncology, 2018
- Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 studyInternational Journal of Hematology, 2017
- Does ponatinib cross the blood–brain barrier?British Journal of Haematology, 2016
- Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MSJournal of Chromatography B, 2013
- Ponatinib in Refractory Philadelphia Chromosome-Positive LeukemiasThe New England Journal of Medicine, 2012
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009